Application of human urinary kininogenase in preparation of medicine for treating hypertension complicated with hyperlipidemia
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of urinary kininogenase and hyperlipidemia, which is applied in the field of medicine, can solve the problems of large toxic side effects, few drugs, and high prices, and achieve a significant synergistic effect
Active Publication Date: 2019-10-08
GUANGDONG TECHPOOL BIO-PHARMA CO LTD
View PDF2 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Existing drugs for the treatment of hypertension and hyperlipidemia are mainly chemical drugs, and they are relatively single. They either treat high blood pressure or treat hyperlipidemia. There are fewer drugs for the combination of the two, and the price is expensive. Long-term use has relatively serious side effects
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0022] Embodiment 1, an injection for the treatment of hypertension combined with hyperlipidemia
[0023] Take filter-sterilized human urinary kininogenase 100PNA units, add an appropriate amount of water for injection to dissolve, then add breviscapine 25mg, dissolve, adjust the pH to neutral, add water for injection to 1000mL, add sodium chloride to adjust isotonicity, Sterile filtration, packing into 1000 ampoules.
Embodiment 2
[0024] Embodiment 2, an injection for the treatment of hypertension combined with hyperlipidemia
[0025] Take filter-sterilized human urinary kininogenase 150PNA units, add appropriate amount of water for injection to dissolve, then add breviscapine 40mg, dissolve, adjust pH to neutral, add water for injection to 1000mL, add sodium chloride to adjust isotonicity, Sterile filtration, packing into 1000 ampoules.
Embodiment 3
[0026] Embodiment 3, an injection for the treatment of hypertension combined with hyperlipidemia
[0027] Take filter-sterilized human urinary kininogenase 200PNA units, add an appropriate amount of water for injection to dissolve, then add breviscapine 45mg, dissolve, adjust the pH to neutral, add water for injection to 1000mL, add sodium chloride to adjust isotonicity, Sterile filtration, packing into 1000 ampoules.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Property
Measurement
Unit
molecular weight
aaaaa
aaaaa
Login to view more
Abstract
The invention belongs to the field of medicine, in particular to a novel medical use of human urinary kininogenase, namely the application of human urinary kallikrein in the preparation of medicine for treating hypertension complicated with hyperlipidemia. Additionally, the present invention provides pharmaceutical compositions comprising human urinary kininogenase, comprising human urinary kininogenase and breviscapine, the main dosage form of which is an injection, usually administered intravenously. In the invention, the human urinary kininogenase composition has remarkable therapeutic effect on hypertension complicated with hyperlipidemia.
Description
technical field [0001] The invention belongs to the field of medicine, and specifically relates to a new medical application of human urinary kininogenase, that is, the application of human urinary kininogenase in the preparation of medicines for treating hypertension combined with hyperlipidemia. Background technique: [0002] Human urinary kininogenase is a refined glycoprotein extracted from healthy male urine, with a molecular weight of about 54,000 Daltons. It can activate the conversion of human plasma kininogen into kinin, dilate blood vessels, increase blood flow, and improve blood circulation. , and also increase the deformability of red blood cells and inhibit platelet aggregation, prolong recalcification time and improve blood viscosity. In recent years, with the in-depth research on human urokininogenase, more and more new uses of human urokininogenase have been found. For example, Chinese patent CN101134106B discloses a pharmaceutical composition containing hum...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more